Welcome to our dedicated page for Arteris news (Ticker: $AIP), a resource for investors and traders seeking the latest updates and insights on Arteris stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arteris's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arteris's position in the market.
Arteris, Inc. (Nasdaq: AIP) announced financial results for Q1 2024, including revenue of $12.9 million, ACV and TTM royalties of $58.2 million, and RPO of $74.7 million. The company reported an operating loss of $9.1 million and a net loss of $9.4 million. Highlights include robust design activity, major license deals, and partnerships in the automotive industry. Second quarter and full year guidance were also provided.
